Management of MSI-H/dMMR Upper and Lower Gastrointestinal Cancers
Clinicians need to be informed about the importance of MSI-H/dMMR testing in patients with GI tumors and updated on the most recent clinical evidence to ensure that they select the most appropriate treatment options for their patients.
Category
- Anal Carcinoma
- Colorectal Cancer
- Gastric/Esophageal Cancer
- Rectal Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Category
- Gastric/Esophageal Cancer
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Event date October 21, 2024